kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human EGFRvIII Protein, His tag, 50 µg  

Recombinant Human EGFRvIII Protein, His tag, 50 µg

Recombinant Human EGFRvIII Protein, Leu 25 - Ser 378, expressed from human HEK293 cells, His tag (HPLC verified) (MALS verified)

recombinant, human, protein, EGFR, ERBB, ERBB1, HER1, PIG61, mENA, EGFRvIII

More details


Availability: within 7 days

533,00 €

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2–7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point.

Recombinant Human EGFRvIII, His Tag (HPLC verified) (EGI-H52H4) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Predicted N-terminus: Leu 25

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 40.5 kDa. The protein migrates as 60-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells"
Cetin, Rieckmann, Hoffer et al
Radiat Oncol (2023) 18 (1), 19
(2) "Pan-cancer molecular analysis of EGFR large fragment deletion in the Asian population"
Pu, Guo, Yu et al
Cancer Med (2023)
(3) "Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors"
Medikonda, Pant, Lim
Adv Exp Med Biol (2023) 1394, 73-84
Showing 1-3 of 1099 papers.

The following products could also be interesting for you: